Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACCD NASDAQ:ALLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACCDAccolade$7.02$7.02$3.08▼$7.03$575.59M2.11.48 million shsN/AALLOAllogene Therapeutics$1.18+1.7%$1.21$0.86▼$3.78$261.82M0.354.40 million shs8.12 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACCDAccolade0.00%0.00%0.00%0.00%+62.12%ALLOAllogene Therapeutics0.00%+9.43%-21.09%-1.69%-56.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACCDAccolade0.7528 of 5 stars1.00.00.04.80.61.70.6ALLOAllogene Therapeutics2.8653 of 5 stars3.43.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACCDAccolade 2.00Hold$6.57-6.41% DownsideALLOAllogene Therapeutics 2.75Moderate Buy$8.44615.63% UpsideCurrent Analyst Ratings BreakdownLatest ACCD and ALLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/4/2025ALLOAllogene TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform8/4/2025ALLOAllogene TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACCDAccolade$446.72M1.29N/AN/A$5.75 per share1.22ALLOAllogene Therapeutics$20K13,090.92N/AN/A$1.55 per share0.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACCDAccolade-$99.81M-$2.25N/AN/AN/A-40.36%-20.74%-11.33%N/AALLOAllogene Therapeutics-$257.59M-$1.11N/AN/AN/AN/A-55.99%-42.75%11/6/2025 (Estimated)Latest ACCD and ALLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ALLOAllogene Therapeutics-$0.28-$0.23+$0.05-$0.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACCDAccoladeN/AN/AN/AN/AN/AALLOAllogene TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACCDAccolade0.672.632.63ALLOAllogene TherapeuticsN/A8.928.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACCDAccolade84.99%ALLOAllogene Therapeutics83.63%Insider OwnershipCompanyInsider OwnershipACCDAccolade8.20%ALLOAllogene Therapeutics13.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACCDAccolade2,35081.99 million74.90 millionOptionableALLOAllogene Therapeutics310221.88 million192.59 millionOptionableACCD and ALLO HeadlinesRecent News About These CompaniesDiffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | DelveInsightAugust 27 at 10:19 PM | finance.yahoo.comAllogene Therapeutics Announces Participation in Upcoming Investor ConferenceAugust 27 at 8:30 AM | globenewswire.comGlobal CAR T-Cell Therapy Market Set to Reach USD 29 Billion by 2029 | MarketsandMarkets™August 27 at 2:19 AM | finance.yahoo.comAllogene Therapeutics management to meet with Piper SandlerAugust 25 at 10:35 PM | msn.comAberdeen Group plc Has $1.27 Million Holdings in Allogene Therapeutics, Inc. $ALLOAugust 24, 2025 | marketbeat.comWilliam Blair Issues Pessimistic Forecast for ALLO EarningsAugust 19, 2025 | marketbeat.comAllogene Therapeutics (NASDAQ:ALLO) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPSAugust 15, 2025 | marketbeat.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | msn.comAllogene Therapeutics Faces Financial Uncertainty Amid New U.S. Tariffs and Regulatory ChallengesAugust 15, 2025 | msn.comAllogene Therapeutics: Q2 Earnings SnapshotAugust 14, 2025 | timesunion.comTAllogene Therapeutics reports Q2 EPS (23c), consensus (27c)August 14, 2025 | msn.comAllogene Narrows Loss in Fiscal Q2August 14, 2025 | aol.comAAllogene outlines clinical milestones with MRD data readout planned for first half 2026 as portfolio advancesAugust 14, 2025 | msn.comAllogene Therapeutics options imply 16.7% move in share price post-earningsAugust 14, 2025 | msn.comAllogene Q2 Cash Tops $300 MillionAugust 14, 2025 | aol.comAAllogene Therapeutics: Important Catalysts Guided For Early 2026August 14, 2025 | seekingalpha.comAllogene's Q2 Loss Narrower Than Expected, Pipeline in FocusAugust 14, 2025 | zacks.comAllogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comAllogene Therapeutics Reports Second Quarter 2025 Financial Results and Business UpdateAugust 13, 2025 | globenewswire.comAllogene Therapeutics Q2 2025 Earnings PreviewAugust 12, 2025 | msn.comA Look at Allogene Therapeutics's Upcoming Earnings ReportAugust 12, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACCD and ALLO Company DescriptionsAccolade NASDAQ:ACCDAccolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington.Allogene Therapeutics NASDAQ:ALLO$1.18 +0.02 (+1.72%) Closing price 04:00 PM EasternExtended Trading$1.20 +0.02 (+1.69%) As of 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike at a Crossroads: AI Halo vs. Risks NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It NIO Just Got Its Second Upgrade of the Month, and It’s Big As Bitcoin Falls and Ethereum Rallies, Coinbase Stock Comes Back Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality Okta: Market Comes to a Boil, Explosive Upside Is Possible MongoDB Roars Back to Life: It’s Not Too Late to Buy More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access